Drug intelligence / Profile preview

Renuva Allograft Adipose Matrix

Development stage: Phase 3
Lead developer: MTF Biologics
Modality: Tissue Cells → Other Cell Types → Cell Therapies
Administration: Subcutaneous, Intradermal

Overview

Renuva Allograft Adipose Matrix is a groundbreaking injectable treatment derived from donated human adipose (fat) tissue. It functions as a natural scaffold that supports adipogenic tissue remodeling. When injected, it creates a honeycomb-like matrix that is gradually replaced with the patient's own fat cells over a period of 3-6 months, providing lasting volume restoration. The matrix contains the same proteins, collagen, and growth factors as natural fat and supports cellular repopulation and vascularization at the treatment site. It's designed for small-volume fat grafting without requiring liposuction or general anesthesia.

Brand names: Renuva
Other names: Allograft Adipose Matrix

Beyond the preview

Go deeper on Renuva Allograft Adipose Matrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renuva Allograft Adipose Matrix.

Explore the full profile